Bronchospasm – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Bronchospasm Market Outlook

Thelansis’s “Bronchospasm Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchospasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Bronchospasm Overview

Bronchospasm, defined as a contraction of the bronchial smooth muscles, narrows the bronchi. This condition is frequently triggered by mechanical or chemical irritants, often in conjunction with underlying airway hyperreactivity, such as in cases of upper respiratory tract infections and smoking. Various stimuli that may precipitate bronchospasm include airway irritation, anaphylaxis, aspiration, pulmonary edema, allergies, acute asthma exacerbations, improper endotracheal tube placement, or extubation-induced spasm. Clinical manifestations of bronchospasm encompass expiratory wheezes, rash, elevated peak airway pressure, desaturation, increased end-tidal CO2 (EtCO2), and a characteristic ‘shark-fin’ appearance on the program. Many individuals experiencing bronchospasm do not have a prior history of obstructive pulmonary disease, and conversely, most patients with obstructive pulmonary disease do not exhibit bronchospasm under anesthesia. Factors that elevate the risk of intraoperative bronchospasm include:

• Recent viral upper respiratory infection
• Recent exacerbation of pulmonary symptoms
• Recent hospital admission for asthma treatment
• Exposure to tobacco smoke

The differential diagnosis of bronchospasm should consider endobronchial intubation, airway foreign body, mucus plugging, circuit or endotracheal tube (ETT) kinking, pulmonary aspiration, and tracheal/bronchial lumen occlusion by the ETT cuff. Treatment strategies for bronchospasm can be categorized into pre-operative and intra-operative phases. Pre-operative management includes supplemental oxygen, inhaled beta-2 (B2) agonists, and intravenous steroids. Medications used in the pre-operative phase include short-acting bronchodilators, long-acting bronchodilators, inhaled steroids, and systemic (oral or intravenous) steroids. Intraoperative management of bronchospasm involves administering volatile anesthetics, inhaled B2 agonists, and intravenous steroids and considering alternative causes of elevated airway pressures, such as kinked tubes or endobronchial intubation.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: